my CGC

Non Invasive Prenatal Test


TOMORROW Prenatal Test is a new CGC Genetics test, performed in maternal blood and with a non-invasive technique, to investigate the presence of trisomy of chromosomes 21, 18 and 13 in fetal DNA, gender identification and detects numerical changes of sex chromosomes (Monosomy X, XXX, XXY, XYY).

Having answers is important and this is in fact a good one!



  • What detects TOMORROW?
    • TOMORROW, the non-invasive study in maternal blood detects:

      Trisomy 21 (Down Syndrome)

      Trisomy 18 (Edwards Syndrome)

      Trisomy 13 (Patau Syndrome)

      Gender identification (fetal sex)

      Numerical changes of sex chromosomes X and Y: Turner syndrome (MX), Klinefelter syndrome (XXY), Triple X syndrome (XXX), Double Y syndrome (XYY)

  • Who should use TOMORROW Prenatal Test?
    • TOMORROW test can be used by all pregnant women, but it is recommended especially for:

      - Pregnant women who wish to screen for the presence of these chromosomal aneuploidies in the fetus without going through an invasive procedure.

      - Pregnant women 35+ years-old.

      - Pregnant women with increased risk for trisomies 21, 18 and 13.

      - Pregnant women with diagnosed trisomy in previous pregnancy.

      - Pregnant women with recurrent abortions history. 

      - Pregnant women who wish to know more about her baby.

      TOMORROW test can also be performed in:

      - Twin pregnancies (2 fetuses)*

      - Egg donation (self-donation or not)


      *Detection of trisomies 21, 18 and 13 and gender identification. Test cannot be performed in case of pregnancies with more than 2 fetuses. Gender identification is performed by detecting the presence or absence of Y chromosome in maternal blood. In case of Y chromosome detection in twin pregnancy (2 fetuses), it is not possible to confirm if one or both fetuses are male.

  • Why is TOMORROW different from Prenatal Screening?
    • Prenatal screening combines biochemical (serum testing) and ultrasound markers and is part of the current pregnancy follow-up protocol. However, this screening test is based on an indirect method which only indicates a probability of presence of trisomy 21, 18 and 13, providing no information either on sex chromosome number (X and Y) or on identification of fetal sex (gender).

      Results are shown through a risk score (e.g. 1/600 or 1/75) which is not always easy to understand, besides a false positive rate between 3 and 5% that requires confirmation by invasive prenatal diagnosis.

      TOMORROW, the new prenatal noninvasive test directly analyzes DNA from the fetal-placental unit, combining detection capacity of numerical changes on chromosome 21, 18, 13, X and Y with identification of fetal sex with high sensitivity and specificity.


      Attention, non-invasive prenatal tests are not all the same!

      Some tests currently available on the market do not include detection of numerical changes of sex chromosomes X and Y or gender identification.

  • Why TOMORROW is so important today?

      TOMORROW Prenatal Test can be performed as early as 10 weeks of pregnancy.
      The report will be available in 6 business days.




      1. Blood sample collection at 10 weeks in pregnancy, or later.

      2. Blood sample analysis.

      3. Results sent from our laboratories directly to your physician.



      Performing the test has no risk of abortion.



      Detection of the most common syndromes: Trisomies 21 (Down Syndrome), 18 and 13, as well as of sex chromosome numerical changes (MX, XXX, XXY, XYY).

      All validation studies published until now have demonstrated high reliability for the non invasive prenatal test.



      TOMORROW can be performed in case of egg donation.



      Detection of trisomy of chromosome 21, 18 and 13 and gender identification can also be performed in twin pregnancies (two fetuses).



      This test uses the most advanced technology available (New Generation Sequencing, NGS).
      For the study of fetal DNA from a maternal blood sample, millions of fragments of DNA (fetal placental unit and maternal) are sequenced and the number of specific sequences is determined for each chromosome. Sample sequences are aligned and compared with sequencing data from a human DNA reference, through a complex bioinformatics analysis. In pregnancies where the fetus is the carrier of a trisomy, the corresponding number of affected chromosome fragments is increased.



      In case of a positive result, confirmation by prenatal invasive diagnosis is advised.

      In this case, CGC Genetics offers at no additional cost: a quick analysis by QF‑PCR, available in 24 to 48 hours, and also chromosome analysis (karyotype), in a fetal sample.